| STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma H Najem, ST Lea, S Tripathi, L Hurley, CH Chen, I William, M Sooreshjani, ... The Journal of Clinical Investigation 134 (12), 2024 | | 2024 |
| Human PD-L2 antibodies and methods of use therefor MA Curran, AR Jaiswal, D Zha, VOO Kui, C Toniatti, B Prinz, N Boland US Patent 11,976,128, 2024 | | 2024 |
| Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia AR Boda, AJ Liu, S Castro-Pando, BT Whitfield, JJ Molldrem, G Al-Atrash, ... Cancer Research Communications 4 (3), 911-918, 2024 | | 2024 |
| Human pd-l1 antibodies and methods of use therefor MA Curran, C Toniatti, AR Jaiswal, D Zha, VOO Kui, B Prinz, N Boland US Patent App. 18/056,711, 2024 | | 2024 |
| Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable … MB LaPelusa, S Chamseddine, L Xiao, E Hasanov, P Bhosale, ... Journal of Clinical Oncology 42 (3_suppl), 561-561, 2024 | | 2024 |
| Depletion of effector regulatory T cells drives major response to induction dual immune checkpoint blockade X Jiang, NP Rudqvist, B Jiang, S Ye, S He, Q Liang, J Dou, M Williams, ... medRxiv, 2024.01. 04.23300616, 2024 | | 2024 |
| Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration A Liu, ST Gammon, F Pisaneschi, A Boda, CR Ager, D Piwnica-Worms, ... JCI insight 9 (1), 2024 | 1 | 2024 |
| Hypoxia-activated prodrug and anti-angiogenic therapy cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration A Liu, ST Gammon, F Pisaneschi, A Boda, CR Ager, D Piwnica-Worms, ... JCI Insight, 2023 | | 2023 |
| Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor M Curran US Patent App. 18/194,360, 2023 | | 2023 |
| Galectin-3 cooperates with CD47 to suppress phagocytosis and T-cell immunity in gastric cancer peritoneal metastases Y Fan, S Song, Y Li, SS Dhar, J Jin, K Yoshimura, X Yao, R Wang, ... Cancer research 83 (22), 3726-3738, 2023 | 3 | 2023 |
| 1115 A novel lioblastoma model resistant to both innate and adaptive immunotherapy S Lea, J Wei, CH Chen, I William, M Curran Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1149 Sensitizing aggressive murine pancreatic cancer to immune checkpoint blockade using a tumor-targeted, STING agonist ‘payloaded’antibody A Boda, S Hegde, S Smith, M Curran Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 853 Evofosfomide potentiates the efficacy of a novel anti-PD-L1/PD-L2 monoclonal antibody against immune excluded tumors A Salameh, P Blezinger, C Gagliardi, M Hemberger, J Barlow, M Curran, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers A Salameh, L Conti, E Bolli, C Cossu, M Iezzi, P Blezinger, C Gagliardi, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Changes in “don't eat me” signaling with radiotherapy in endometrial cancer (2301) J Son, B Turner, B Lawson, C Sun, D Hong, M Curran Gynecologic Oncology 176, S316, 2023 | | 2023 |
| Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation Y Zhang, Z Zhao, LA Huang, Y Liu, J Yao, C Sun, Y Li, Z Zhang, Y Ye, ... Cell Metabolism 35 (8), 1457-1473. e13, 2023 | 5 | 2023 |
| Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease CH Chen, RL Chin, GP Hartley, ST Lea, BJ Engel, CE Hsieh, R Prasad, ... Neuro-oncology 25 (8), 1415-1427, 2023 | 5 | 2023 |
| Single-cell RNA and T cell receptor (TCR) sequencing in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC) after induction CTLA4 and PD-1 immune … X Jiang, NP Rudqvist, S Liang, S Ye, S He, Q Liang, MA Curran, B Jiang, ... Journal of Clinical Oncology 41 (16_suppl), 6056-6056, 2023 | | 2023 |
| Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial. M Nardo, M Reilley, A Biter, JA Lim, SA Bean, LM Nguyen, P Bhosale, ... Journal of Clinical Oncology 41 (16_suppl), 2564-2564, 2023 | | 2023 |
| Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance Y Chu, E Dai, Y Li, G Han, G Pei, DR Ingram, K Thakkar, JJ Qin, M Dang, ... Nature medicine 29 (6), 1550-1562, 2023 | 86 | 2023 |
